Corcept Therapeutics Incorporated

Corcept Therapeutics Misses on Revenue, Stock Down 2.58%

Corcept Therapeutics reported a loss of $0.10 per share, which was better than expected, but the lack of revenue figures may have raised concerns among investors. The stock fell by 2.58% in response to the overall uncertainty and absence of guidance. Investors will likely be looking for more clarity in future reports.